Insider Transactions in Q1 2025 at Kiniksa Pharmaceuticals, Ltd. (KNSA)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 20
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
15,944
-40.54%
|
$366,712
$23.11 P/Share
|
|
Mar 20
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,944
+28.85%
|
$191,328
$12.97 P/Share
|
|
Mar 19
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,879
-27.52%
|
$204,217
$23.1 P/Share
|
|
Mar 19
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,879
+21.58%
|
$106,548
$12.97 P/Share
|
|
Mar 17
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
11,464
-32.9%
|
$263,672
$23.1 P/Share
|
|
Mar 17
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,464
+24.75%
|
$137,568
$12.97 P/Share
|
|
Mar 16
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
577
-0.73%
|
$12,694
$22.61 P/Share
|
|
Mar 16
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+2.44%
|
-
|
|
Mar 16
2025
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
328
-1.18%
|
$7,216
$22.61 P/Share
|
|
Mar 16
2025
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
774
+2.71%
|
-
|
|
Mar 16
2025
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
292
-1.22%
|
$6,424
$22.61 P/Share
|
|
Mar 16
2025
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
994
+4.0%
|
-
|
|
Mar 16
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
448
-1.88%
|
$9,856
$22.61 P/Share
|
|
Mar 16
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
872
+3.53%
|
-
|
|
Mar 16
2025
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
507
-0.94%
|
$11,154
$22.61 P/Share
|
|
Mar 16
2025
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,725
+3.11%
|
-
|
|
Mar 16
2025
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,004
-2.33%
|
$44,088
$22.61 P/Share
|
|
Mar 16
2025
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,569
+7.09%
|
-
|
|
Mar 12
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
36,372
-61.3%
|
$800,184
$22.25 P/Share
|
|
Mar 12
2025
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
36,372
+38.01%
|
$400,092
$11.97 P/Share
|
|
Mar 12
2025
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
9,051
-25.44%
|
$199,122
$22.45 P/Share
|
|
Mar 12
2025
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,051
+20.28%
|
$99,561
$11.1 P/Share
|
|
Mar 10
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
12,409
-13.95%
|
$260,589
$21.06 P/Share
|
|
Mar 10
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+7.29%
|
$21,000
$3.8 P/Share
|
|
Feb 10
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
14,000
-14.59%
|
$266,000
$19.57 P/Share
|
|
Feb 10
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+6.8%
|
$21,000
$3.8 P/Share
|
|
Jan 15
2025
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
469
+1.71%
|
$7,504
$16.0 P/Share
|
|
Jan 15
2025
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,118
+4.66%
|
$17,888
$16.0 P/Share
|
|
Jan 13
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
14,000
-6.91%
|
$252,000
$18.61 P/Share
|
|
Jan 13
2025
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+6.37%
|
$21,000
$3.8 P/Share
|